L. crispatus M247 Doubled HR-HPV Clearance in 4-Month RCT

High-risk HPV (HR-HPV) infects approximately 300 million women globally and is the necessary cause of virtually all cervical cancers. For the overwhelming majority of those infected, the immune system clears the virus within one to two years without intervention. The question researchers have increasingly asked is whether vaginal microbiome composition plays a meaningful role in that clearance — and if so, whether it can be shifted therapeutically. A 2025 randomized controlled trial from Di Pierro and colleagues directly tested that question with oral Lactobacillus crispatus M247, the species that defines the healthiest known vaginal community state.

This trial is notable for several reasons beyond its headline numbers. It used an oral route of administration — not a vaginal suppository — which has significant practical implications for how we think about daily food-based consumption of live fermented milks. It characterized microbiome composition at baseline and follow-up using 16S rRNA sequencing, allowing the team to directly map community state shifts alongside viral clearance outcomes. And it enrolled women with confirmed HR-HPV positivity across a range of cytological presentations — not just women with clean baselines unlikely to benefit — making the population clinically meaningful. The results were substantial enough to warrant careful attention, alongside honest acknowledgment of what a 62-person single-blind trial can and cannot tell us.

Key Findings

HR-HPV = high-risk human papillomavirus. CST I = Community State Type I (L. crispatus-dominated vaginal microbiome). OR = odds ratio. PAP smear negativity and HPV clearance assessed at 4-month endpoint. Clearance defined as confirmed HR-HPV negativity at follow-up.

Mechanism: How L. crispatus Acts on the Vaginal Microbiome

Lactic Acid Production and Vaginal pH Regulation

Lactobacillus crispatus is one of the most efficient lactic acid-producing organisms in human biology. It generates both D- and L-lactic acid isomers through homofermentation, driving vaginal pH below 4.5 — the threshold associated with suppression of most pathogenic organisms. At this pH, the activity of epithelial-degrading proteases is reduced, the integrity of the cervicovaginal mucus layer is preserved, and the local environment becomes inhospitable to organisms including Gardnerella vaginalis, Prevotella species, and other anaerobes that characterize the dysbiotic community states associated with higher HPV persistence. L. crispatus also produces hydrogen peroxide and bacteriocins — small antimicrobial peptides — that further suppress competing microorganisms through direct membrane disruption. The net ecological result of sustained L. crispatus colonization is a low-diversity, high-dominance community the field has classified as Community State Type I (CST I). Epidemiological data consistently link CST I to lower rates of sexually transmitted infection acquisition, faster clearance of HPV, and lower cervical cancer risk — though the precise causal pathway from microbiome composition to immune outcome has been difficult to isolate in observational data alone. This trial is among the first to probe it experimentally.

Reduced Microbial Richness and Local Antiviral Immune Modulation

The immunological dimension of this trial is where the mechanism becomes particularly specific. The authors observed that reduced vaginal microbial richness — not just increased L. crispatus relative abundance — correlated independently with HPV clearance. This distinction matters because it implicates the community composition, not merely a single organism's presence. High-diversity vaginal communities dominated by anaerobic species rather than Lactobacillus are consistently associated with elevated local concentrations of pro-inflammatory cytokines including IL-1β, IL-6, IL-8, and TNF-α. These cytokines are part of a persistent low-grade immune activation that appears to impair the coordinated antiviral response required for HPV clearance — including CD4+ T helper cell coordination and the production of neutralizing secretory IgA antibodies at the cervicovaginal mucosa. By shifting the community toward CST I, oral supplementation with L. crispatus M247 appears to reduce this background inflammatory signal and create a local immune environment more conducive to viral clearance. The 3.2-fold increase in clearance odds observed in this trial is consistent with this mechanistic model. It is not, however, direct proof of it — the trial did not measure cytokine concentrations or mucosal immunoglobulin levels, and confirming the pathway requires trials with direct immune endpoint measurement alongside microbiome characterization.

Vital Yogurts Connection: Big Sur

Big Sur contains Lactobacillus crispatus — the same species studied in this trial. L. crispatus was selected for Big Sur specifically because of its role in vaginal microbiome ecology: it is the defining organism of CST I, the community state associated with the lowest rates of HPV persistence and cervical abnormality in population-level microbiome research. The evidence base for this culture's role in vaginal health is not new — it spans a decade of epidemiological and ecological data. What this 2025 trial adds is the first randomized controlled evidence that oral supplementation with L. crispatus can shift vaginal community state and correlate meaningfully with improved HPV clearance outcomes in a clinical population.

The oral route tested in this study is how Big Sur is consumed — as a daily live fermented milk. This matters because a common assumption in vaginal microbiome research has been that oral administration would have limited impact on vaginal community composition relative to direct vaginal application. This trial challenges that assumption with randomized controlled evidence. The microbiome sequencing data showing CST I shift following oral supplementation suggests that at least some fraction of orally consumed L. crispatus reaches and colonizes within the vaginal niche — a finding with substantive implications for how daily fermented milk consumption should be understood in the context of women's reproductive and microbiome health.

Protocol Implications

The trial used 4 months of daily oral supplementation as its intervention period, with outcomes assessed at the end of that window. There was no interim assessment point, so the timeline at which microbiome shift begins — and whether there is an early signal or a delayed community-stabilization effect — cannot be determined from this data alone. What the study establishes is that 4 months of consistent daily supplementation is sufficient to observe a statistically meaningful difference in HPV clearance rates and CST I community composition. For practical application, this suggests that a minimum 4-month commitment to daily L. crispatus consumption is likely required before community state shifts would be expected to stabilize and translate to measurable outcomes. Shorter durations have not been studied in this specific context and cannot be extrapolated from this trial's design. Women who are HPV-positive and considering the role of microbiome in their clinical situation should do so in direct consultation with their gynecologist, and should not modify recommended cervical screening protocols during any supplementation period.

Vital Yogurts — Big Sur

The culture studied is in Big Sur.

Lactobacillus crispatus — M247 species

Big Sur is formulated with Lactobacillus crispatus, the CST I-defining culture studied in this 2025 multi-center RCT. The trial's finding — that daily oral supplementation was associated with a 3.2-fold increase in HR-HPV clearance odds and a sequencing-confirmed shift toward CST I community state — was produced by the same species found in every serving of Big Sur.

Valley — 20B CFU Reserve — 40B CFU Summit — 60B CFU

Shop Big Sur

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your diet or supplement routine. The studies cited are referenced for informational context; Vital Yogurts makes no therapeutic or disease treatment claims.